ResultsIQ

ResultsIQ › Latest results › Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited Q1 FY27 earnings call summary

NSE: INDSWFTLAB · BSE: 532305

Earnings call of 17 Aug 2026, summarised by AI from the filing.

Ind-Swift Laboratories Q1 FY27 operating income ₹186.08 cr, EBITDA margin 17.91%, with CDMO partnerships commercialised and ₹900 cr revenue expected this year.

Key takeaways

  1. CDMO ramp Viatris, Manx and Arrotex partnerships commercialised; ₹200-220 cr incremental FY27 revenue, ramping over two years.
  2. Export mix Own-brand exports rose to 57.20% of Q1 FY27 sales from 48% in Q1 FY26, driving margin expansion.
  3. Capacity risk Revenue targets depend on completing capacity expansion; new partnerships will not come this year.

Original filing on BSE

Ind-Swift Laboratories Limited Q1 FY27 results

As filed: Revenue ₹191 cr (+25% year on year), EBITDA ₹33.4 cr (+300% year on year), PAT ₹24.7 cr (+174% year on year), EBITDA margin 17.5% (+1,000 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹170 cr (+23% year on year), EBITDA ₹20.6 cr, PAT ₹15.1 cr (+22% year on year), EBITDA margin 12.1% (+1,000 bps). Score 48 of 100, In line with trend. Revenue and profit before exceptional items growth were in line with the company's own trend. EBITDA margin rose 1000 bps year on year. Tax rate -26%. Profit fell 23% from last quarter. Share price after the results: +49.0% in 28 days (Nifty 500: +0.6%).
  • Q3 FY26: Revenue ₹151 cr (+300% year on year), EBITDA ₹4.2 cr, PAT ₹9.5 cr, EBITDA margin 2.8%. Score 75 of 100, Above trend. Revenue growth was well above the company's own trend. Other income 168% of PBT. Share price after the results: +21.0% in 30 days (Nifty 500: −1.1%).
  • Q2 FY26: Revenue ₹153 cr (+300% year on year), EBITDA ₹1.0 cr, PAT ₹8.0 cr, EBITDA margin 0.7% (+1,000 bps). Score 79 of 100, Above trend. Revenue growth was well above the company's own trend. EBITDA margin rose 1000 bps year on year. Other income 180% of PBT. Profit fell 11% from last quarter. Share price after the results: −5.6% in 28 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹153 cr (+300% year on year), EBITDA ₹3.0 cr, PAT ₹9.0 cr (+300% year on year), EBITDA margin 2.0% (+1,000 bps). Score 85 of 100, Above trend. Revenue and profit growth were well above the company's own trend. EBITDA margin rose 1000 bps year on year. Other income 150% of PBT. Profit fell 96% from last quarter. Share price after the results: +6.2% in 30 days (Nifty 500: +1.9%).
  • Q4 FY25: Revenue ₹138 cr (−65% year on year), EBITDA −₹10.0 cr, PAT ₹222 cr, EBITDA margin -7.3% (+217 bps). Score 39 of 100, Below trend. Revenue growth was well below the company's own trend. EBITDA margin rose 217 bps year on year. Tax rate 3%.
  • Q3 FY25: Revenue ₹9.0 cr, EBITDA −₹15.0 cr, PAT ₹0.0 cr, EBITDA margin -166.7%. Not scored. Too small to score: quarter revenue ₹9.0 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little.
  • Q2 FY25: Revenue ₹12.0 cr, EBITDA −₹12.0 cr, PAT ₹0.0 cr, EBITDA margin -100.0%. Not scored. Too small to score: quarter revenue ₹12.0 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little.

Past price moves after results do not indicate future moves. Not a recommendation.

Ind-Swift Laboratories Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.